BioCryst Appoints Jinky Ang Rosselli Chief Data and
RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the appointment of Jinky Ang...
Source: globenewswire.com
Page 10 - John Bluth News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from John Bluth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In John Bluth Today - Breaking & Trending Today
BioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer
BioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com
BioCryst Pharmaceuticals (BCRX) Q1 2021 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) Q1 2021 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble. BioCryst Pharmaceuticals (NASDAQ: BCRX) Ladies and gentlemen, thank you for standing by, and welcome to the BioCryst's first-quarter 2021 earnings call. [Operator instructions] I would now like to hand the conference over to your speaker today, Mr. John Bluth of BioCryst. John, the floor is yours. John Bluth -- Senior Vice President, Investor Relations and Corporate Communications Thanks, Jay. Good morning and welcome to BioCr...
Source: msn.com
BioCryst Receives European Commission Approval of ORLADEYO™
ORLADEYO ™ (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. The full European Summary of Product Characteristics (SMPC) for ORLADEYO will be available from the European Medicines Association website at About BioCryst Pharmaceuticals BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet ...
Source: globenewswire.com
BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
ORLADEYO ™ (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. The full European Summary of Product Characteristics (SMPC) for ORLADEYO will be available from the European Medicines Association website at About BioCryst Pharmaceuticals BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet ...
Source: benzinga.com